Physician profile
Carmelo C Mendiola
NPI 1023063922
$6,756.52
in general payments reported to CMS, 2019-2025
38 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,235 · 2020: $977 · 2021: $1,031 · 2022: $822 · 2023: $796 · 2024: $887 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.45 |
| Education | $210.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,783.18 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $920.36 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $581.69 | 2019-2025 | Lokelma, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $566.08 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $450.05 | 2019-2025 | Verquvo, Belsomra |
| Amgen INC. | $448.78 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $432.05 | 2019-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $209.46 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.81 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $139.06 | 2024-2025 | Jynarque, Rexulti |
| Sanofi-Aventis U.S. LLC | $110.90 | 2019-2022 | |
| Abbvie INC. | $106.12 | 2020-2023 | |
| Amarin Pharma, INC. | $102.13 | 2019-2021 | |
| Abbott Laboratories | $74.56 | 2021-2024 | Freestyle Libre 2, Proclaim |
| Akebia Therapeutics INC | $65.48 | 2020-2025 | Vafseo, Auryxia |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmelo Mendiola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.